Drug intelligence / Profile preview

anti-MUC1

Development stage: Preclinical
Lead developer: Iaso Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Anti-MUC1 is a preclinical-stage monoclonal antibody (mAb) being developed by Iaso Therapeutics for the treatment of cancer. The antibody is designed to target Mucin 1 (MUC1), a transmembrane glycoprotein that is overexpressed and aberrantly glycosylated in a variety of epithelial tumors, including breast, lung, and pancreatic cancers. MUC1 overexpression is associated with increased tumor cell proliferation, survival, and metastasis. By binding to MUC1, this therapeutic candidate aims to disrupt oncogenic signaling pathways and potentially induce antibody-dependent cellular cytotoxicity (ADCC) or other immune-mediated mechanisms to eliminate cancer cells.

Other names: Anti-MUC1Anti-MUC-1Anti-MUC 1

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on anti-MUC1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-MUC1.

Explore the full profile